Presenting at the 2024 Wells Fargo Healthcare Conference, Edwards Lifesciences said that, “There are estimates on Wall Street that show earnings per share going up in 2025, that’s not going to happen. Our earnings per share will be lower in 2025 than they are in 2024. But one of the biggest influences on, of course, is what happens with the top-line. And as we get closer to the end of the year, we’ll have a better feel of what the top-line looks like and then how that flows down the P&L… But what’s especially important to note is 2025 is going to be a transition year for us in terms of earnings and margins. In 2025, we expect that will be a base from which we resume EPS growth in ’26 and beyond.” Shares are down almost 5% to $65.56 in morning trading,
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences down 6% as company presents at Wells Fargo conference
- Edwards Lifesciences Enhances Shareholder Value Post-Divestiture
- Becton Dickinson completes purchase of Critical Care from Edwards Lifesciences
- Edwards Lifesciences call volume above normal and directionally bullish
- Edwards Lifesciences put volume heavy and directionally bearish